Monday, October 12, 2026

Chocolate Lovers Rejoice: A 2009 Study Shows Cocoa May Protect Your Liver!

ViaNews Editorial Team

January 20, 2023

Cocoa tree

Cocoa, the main ingredient in chocolate, has long been known to have potential health benefits because of its high content of antioxidant compounds. A 2009 study has shown that cocoa may also have a specific protective effect on the liver. The study found that when liver cells were exposed to a drug that can damage the liver, cocoa extracts were able to prevent the cells from dying.

According to the research, the body uses a mechanism called autophagy to remove damaged cells, which is how cocoa extracts were able to accomplish this.
When autophagy is turned on, damaged cells are ultimately engulfed and destroyed by the body before they can do any more damage.
In this instance, the research discovered that the cocoa extracts may raise the levels of a protein called Beclin 1, which is involved in the autophagic process, and that this in turn helped to shield the liver cells from the harmful effects of the drug.

The study was conducted in a lab setting, and further research is required to fully understand the possible health advantages of cocoa in people.
However, the results imply that cocoa can be included in the group of natural substances that have the ability to stop or even reverse liver damage.

While more research is needed to fully understand the potential health benefits of cocoa, this study suggests that it may be a promising natural option for liver health. Adding cocoa to your diet in the form of dark chocolate, cocoa powder or cocoa nibs is a delicious way to potentially promote liver health. However, it's important to keep in mind that chocolate also contains sugar and fat, so it's best to consume it in moderation.

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Agentic AI Rewires Enterprise Software: Platform Incumbents, Governance, and a Funded Startup Wave
Enterprise software is being rebuilt around autonomous AI agents. Incumbents and large platforms (SAP with its Autonomous Suite and Joule, Zeta with AthenaOS/AIM/Athena MCP, Meta with its new Enterprise Platform) are racing to own the agent layer. Meanwhile, seed and Series A money flows to finance-office and vertical startups (Dextr, Latitude, Dentira, Light), and consolidation continues through acquisitions (Tiny–Oso Cloud, Harvey–Guardrails AI). Investor commentary stresses that AI is better at disrupting around the edges of systems of record than at replacing them, that it should not be trusted with finance calculations, and that governance must be enforced by the system rather than left to agents.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,369 source documents archived
Query this data → isubstrate.com